After-surgery targeted pill to prevent relapse in EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to under 80 years old, and provide written consent
- Have had complete surgery for stage IB to IIIB non-small-cell lung cancer (NSCLC) with no cancer left at the margins (R0 resection)
- Your tumor must have specific EGFR mutations (exon 19 deletion, L858R in exon 21, or L861Q, or G719X)
- Be well enough for treatment (doctor rates you as ECOG 0–1) and expect to live at least 12 weeks
- Have blood, liver, and kidney lab results high enough for medication safety
- Women must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.